A little less than a year ago The Medicines Co. said its third late-stage trial of cangrelor managed to do something that the first two had failed at: Conclusively demonstrate the superiority of its blood thinner over Plavix.

…read more

Source: FDA reviewers paint radically contrasting pictures of The Medicines Co.’s cangrelor


0 No comments